RxDoctor Payments DataLook up a doctor →

Christoph Cannon, MD

Cardiovascular Disease · Boston, MANPI 1548227960

Payments from drug & device makers

$620,790in general payments, 2019–2025

Across 235 payments — averaging $2641.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$178K
  • Boehringer Ingelheim$107K
  • Merck$83K
  • Boehringer Ingelheim International GmbH$57K
  • Sanofi US Services Inc.$36K
  • Janssen Research & Development, LLC$32K
  • plus $129K from 19 others
$110,918in research payments, 2019–2025

Across 79 payments — averaging $1404.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$70K
  • Regeneron$12K
  • Amryt Pharma Holdings Ltd$10K
  • Novo Nordisk AS$9K
  • Amgen$7K
  • Chiesi USA, Inc.$2K

What the payments were for

  • Consulting fees$303,60175%
  • Speaking & faculty fees$80,12420%
  • Travel & lodging$16,9794%
  • Food & beverage$1,4270%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$620,790 in reported general payments places this provider in the 90th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$103,031
Medicare patients
1,407
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab167$186,425
EliquisApixaban112$159,101
Praluent PenAlirocumab83$83,004
XareltoRivaroxaban49$68,094
JardianceEmpagliflozin28$42,687
EntrestoSacubitril/Valsartan17$23,173
Ezetimibe359$18,965
VascepaIcosapent Ethyl18$16,518
NexletolBempedoic Acid12$9,278
Rosuvastatin Calcium283$6,864
Metoprolol Succinate250$4,822
Atorvastatin Calcium251$4,101
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$1,257
Lisinopril132$1,199
Amlodipine Besylate137$1,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$5,812$159,101112 claims
Boehringer IngelheimJardiance$107,088$42,68728 claims
NovartisEntresto$10,585$23,17317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →